431 related articles for article (PubMed ID: 31803194)
1. Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
Lazarova M; Steinle A
Front Immunol; 2019; 10():2689. PubMed ID: 31803194
[TBL] [Abstract][Full Text] [Related]
2. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
3. The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M; Steinle A
Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
[TBL] [Abstract][Full Text] [Related]
4. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
5. The killing effect of Tanshinol on breast cancer cells: insight into the reversion of TGF-β1-mediated suppression of NK cell functions.
Yang C; Qian C; Zhang T; Zheng W; Zhang S; Wang S; Wang A; Zhao Y; Lu Y
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1106-1118. PubMed ID: 34856757
[No Abstract] [Full Text] [Related]
6. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
7. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
8. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
9. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
[TBL] [Abstract][Full Text] [Related]
10. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Schmiedel D; Mandelboim O
Front Immunol; 2018; 9():2040. PubMed ID: 30254634
[TBL] [Abstract][Full Text] [Related]
11. Regulatory NK1.1
Lin Z; Han S; Qian X; Hu C; Xiao W; Qian L; Zhang Y; Ding Y; Jia X; Zhu G; Gong W
Cancer Immunol Immunother; 2018 Jul; 67(7):1159-1173. PubMed ID: 29802426
[TBL] [Abstract][Full Text] [Related]
12. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis.
Guo SW; Du Y; Liu X
Hum Reprod; 2016 Jul; 31(7):1462-74. PubMed ID: 27130956
[TBL] [Abstract][Full Text] [Related]
14. Targeting NKG2D in tumor surveillance.
Hayakawa Y
Expert Opin Ther Targets; 2012 Jun; 16(6):587-99. PubMed ID: 22530569
[TBL] [Abstract][Full Text] [Related]
15. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
16. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
17. NKG2D ligand expression in pediatric brain tumors.
Haberthur K; Brennan K; Hoglund V; Balcaitis S; Chinn H; Davis A; Kreuser S; Winter C; Leary SE; Deutsch GH; Ellenbogen RG; Crane CA
Cancer Biol Ther; 2016 Dec; 17(12):1253-1265. PubMed ID: 27834580
[TBL] [Abstract][Full Text] [Related]
18. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
20. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
